

LUD 5353.5 DIV JEL/NDH (10016355)

corrected, because nucleotides 1576-1578 of SEQ ID NOS: 13 and 14 ("TGA") constitute a "stop" codon, as is well known in the art. As such, these do not code, and are properly deleted from the open reading frame.

A Showing of Changes accompanies this Preliminary Amendment.

It is believed that this preliminary amendment should facilitate prompt action and allowance of this application.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.

A handwritten signature in black ink, appearing to read "Norman D. Hanson", is written over a horizontal line.

Norman D. Hanson, Esq.
Registration No. 30,946


666 Fifth Avenue
New York, New York 10103-3198
(212) 318-3000

LUD-5353.5 JEL/NDH (10016358)

• VIA FACSIMILE

I hereby certify that this correspondence is being facsimile transmitted to the
Commissioner of Patents and Trademarks, Washington, D.C. 20231 on
June 7, 2002.

Fulbright & Jaworski L.L.P.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant : Beatrice GAUGLER et al.
Serial No. : 09/579,543
Filed : May 26, 2000
For : ISOLATED NUCLEIC ACID MOLECULES CODING FOR
TUMOR REJECTION ANTIGEN PRECURSOR MAGE-4
AND 41 AND USES THEREOF
Art Unit : 1642
Examiner : Alana Harris

June 7, 2002

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

S I R:

SHOWING OF CHANGES

IN THE CLAIMS

Amend claims 38, 39, 40, 41, 43, 44, 58, 59, 60, 64 and 66 as follows:

E
Claim 38 (Amended): An isolated nucleic acid molecule which encodes a tumor rejection antigen precursor expressed in melanoma cells, wherein the complementary sequence of said isolated nucleic acid molecule hybridizes to the nucleotide sequence set forth in SEQ ID NO: 13, 14 or 15 at 0.1XSSC, 0.1%SDS for 30 minutes, at 65°C.

Claim 39 (Amended): An isolated nucleic acid molecule which encodes a tumor rejection antigen precursor expressed in melanoma cells, wherein the complementary sequence of said isolated nucleic acid molecule hybridizes to the

LUD 5353.5 DIV JEL/NDH (10016355)

nucleotide sequence set forth in SEQ ID NO: 13, 14 or 15 at 0.1XSSC
0.1%SDS for 30 minutes, at 65°C.

Claim 40 (Amended): An isolated nucleic acid molecule which encodes a tumor rejection antigen expressed in melanoma cells, wherein the complementary sequence of said isolated nucleic acid molecule hybridizes to the nucleotide sequence set forth in SEQ ID NO: 13, 14 or 15 at 0.1XSSC, 0.1%SDS, for 30 minutes, at 65°C.

Claim 41 (Amended): An isolated nucleic acid molecule which encodes a tumor rejection antigen precursor expressed in melanoma cells, wherein the complementary sequence of said isolated nucleic acid molecule hybridizes to the nucleotide sequence set forth in SEQ ID NO: 13, 14 or 15 at 0.1XSSC 0.1%SDS, for 30 minutes at 65°C.

Claim 43 (Amended): An isolated cDNA molecule which encodes a fragment of a tumor rejection antigen precursor expressed in melanoma cells, wherein said fragment is processed by cell to a tumor rejection antigen, wherein the complementary sequence of said isolated nucleic acid molecule hybridizes to nucleotides 625-157[8]5 of SEQ ID NO: 13, nucleotides 625-157[8]5 of SEQ ID NO: 14, or nucleotides 1-670 of SEQ ID NO: 15 at 0.1XSSC, 0.1%SDS for 30 minutes at 65°C.

Claim 44 (Amended): An isolated cDNA molecule which encodes a fragment of a tumor antigen expressed by melanoma cells, said tumor rejection antigen consisting of an amino acid sequence that is part of a tumor rejection antigen precursor, wherein said tumor rejection antigen precursor is encoded by a nucleic acid molecule the complementary sequence of which hybridizes to nucleotides 625-157[8]5 of SEQ ID NO: 13, nucleotides 625-157[8]5 of SEQ ID NO: 14, or nucleotides 1-670 of SEQ ID NO: 15 at 0.1XSSC, 0.1%SDS for 30 minutes at 65°C.

Claim 58 (Amended): An isolated nucleic acid molecule which encodes a tumor rejection antigen precursor expressed by melanoma cells encoded by nucleotides 625-157[8]5 of SEQ ID NO: 13, nucleotides 625-157[8]5 of SEQ ID NO: 14, or nucleotides 1-670 of SEQ ID NO: 15.

LUD 5353.5 DIV JEL/NDH (10016355)

Claim 59 (Amended): An isolated nucleic acid molecule which encodes a tumor rejection antigen precursor expressed by melanoma cells that is encoded by nucleotides 625-157[8]5 of SEQ ID NO: 13, nucleotides 625-157[8]5 of SEQ ID NO: 14, or nucleotides 1-670 of SEQ ID NO: 15.

Claim 60 (Amended): An isolated nucleic acid molecule which encodes a tumor rejection antigen expressed by melanoma cells, the amino acid sequence of which consists of amino acid sequence that is a part of the amino acid sequence encoded by nucleotides 625-157[8]5 of SEQ ID NO: 13, nucleotides 625-157[8]5 of SEQ ID NO: 14, or nucleotides 1-670 of SEQ ID NO: 15.

Claim 61 (Amended): An isolated genomic DNA molecule which encodes a MAGE4 or MAGE-41 tumor rejection antigen precursor expressed by melanoma cells comprising one of:

- (i) nucleotides 625-157[8]5 of SEQ ID NO: 13;
- (ii) nucleotides 625-157[8]5 of SEQ ID NO: 14; or
- (iii) nucleotides 1-670 of SEQ ID NO: 15.

Claim 66 (Amended): An isolated genomic DNA molecule consisting of:

- (i) nucleotides 625-157[8]5 of SEQ ID NO: 13; (ii)
- (ii) nucleotides 625-157[8]5 of SEQ ID NO: 14; or
- (iii) nucleotides 1-670 of SEQ ID NO: 15.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.



Norman D. Hanson, Esq.
Registration No. 30,946

666 Fifth Avenue
New York, New York 10103-3198
(212) 318-3000